MX2023001885A - Derivados de imidazo[1,2-a]piridina y [1,2,4]triazolo[1,5-a]piridi na como inhibidores del receptor tipo toll 9 (tlr9) para el tratamiento de la fibrosis. - Google Patents

Derivados de imidazo[1,2-a]piridina y [1,2,4]triazolo[1,5-a]piridi na como inhibidores del receptor tipo toll 9 (tlr9) para el tratamiento de la fibrosis.

Info

Publication number
MX2023001885A
MX2023001885A MX2023001885A MX2023001885A MX2023001885A MX 2023001885 A MX2023001885 A MX 2023001885A MX 2023001885 A MX2023001885 A MX 2023001885A MX 2023001885 A MX2023001885 A MX 2023001885A MX 2023001885 A MX2023001885 A MX 2023001885A
Authority
MX
Mexico
Prior art keywords
fibrosis
pyridine
triazolo
imidazo
treatment
Prior art date
Application number
MX2023001885A
Other languages
English (en)
Spanish (es)
Inventor
Alicia Regueiro-Ren
Andrew P Degnan
David S Yoon
Gang Wu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023001885A publication Critical patent/MX2023001885A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2023001885A 2020-08-19 2021-08-18 Derivados de imidazo[1,2-a]piridina y [1,2,4]triazolo[1,5-a]piridi na como inhibidores del receptor tipo toll 9 (tlr9) para el tratamiento de la fibrosis. MX2023001885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063067452P 2020-08-19 2020-08-19
PCT/US2021/046420 WO2022040259A1 (en) 2020-08-19 2021-08-18 Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
MX2023001885A true MX2023001885A (es) 2023-03-10

Family

ID=77693624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001885A MX2023001885A (es) 2020-08-19 2021-08-18 Derivados de imidazo[1,2-a]piridina y [1,2,4]triazolo[1,5-a]piridi na como inhibidores del receptor tipo toll 9 (tlr9) para el tratamiento de la fibrosis.

Country Status (13)

Country Link
US (1) US12486267B2 (enExample)
EP (1) EP4200297B1 (enExample)
JP (1) JP7813775B2 (enExample)
KR (1) KR20230053644A (enExample)
CN (1) CN116096717B (enExample)
AR (1) AR123281A1 (enExample)
AU (1) AU2021328575A1 (enExample)
BR (1) BR112023002737A2 (enExample)
CA (1) CA3190065A1 (enExample)
IL (1) IL300727A (enExample)
MX (1) MX2023001885A (enExample)
TW (1) TW202227432A (enExample)
WO (1) WO2022040259A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
EP4479407A1 (en) * 2022-02-18 2024-12-25 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9
CN120230100B (zh) * 2025-05-30 2025-09-05 中国药科大学 一种咪唑并[1,2-a]吡嗪或咪唑并[1,2-a]吡啶类化合物及其医药用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
RU2012116207A (ru) 2009-09-24 2013-10-27 Ф.Хоффманн-Ля Рош Аг Производные индола в качестве модуляторов crac
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
US9193724B2 (en) 2011-09-22 2015-11-24 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20130158049A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
US20130158066A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
WO2013156431A1 (en) 2012-04-17 2013-10-24 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives
JP6168055B2 (ja) 2012-06-18 2017-07-26 住友化学株式会社 縮合複素環化合物
CA2933466A1 (en) 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
JP6695865B2 (ja) * 2014-09-16 2020-05-20 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する有害生物防除に活性である四環式誘導体
BR112018006005A2 (pt) * 2015-09-29 2018-10-30 Oncotherapy Science Inc composto bicíclico e uso do mesmo para inibição de suv39h2
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
EP3538513A1 (en) * 2016-11-11 2019-09-18 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
WO2018165112A1 (en) * 2017-03-09 2018-09-13 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting histone methyltransferase
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
WO2019099336A1 (en) * 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
JP7289301B2 (ja) 2017-12-18 2023-06-09 ブリストル－マイヤーズ スクイブ カンパニー ４－アザインドール化合物
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
CN111511730B (zh) 2017-12-19 2023-07-25 百时美施贵宝公司 可用作tlr抑制剂的被酰胺取代的吲哚化合物
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
EP4089096A4 (en) * 2020-01-09 2024-01-03 Sumitomo Chemical Company, Limited HETEROCYCLIC COMPOUND AND MEANS THEREOF FOR CONTROLLING HARMFUL ARTHROPODS

Also Published As

Publication number Publication date
CA3190065A1 (en) 2022-02-24
US20240067638A1 (en) 2024-02-29
IL300727A (en) 2023-04-01
JP2023538393A (ja) 2023-09-07
BR112023002737A2 (pt) 2023-03-14
EP4200297A1 (en) 2023-06-28
JP7813775B2 (ja) 2026-02-13
US12486267B2 (en) 2025-12-02
WO2022040259A1 (en) 2022-02-24
AR123281A1 (es) 2022-11-16
CN116096717B (zh) 2026-04-10
EP4200297B1 (en) 2026-05-13
TW202227432A (zh) 2022-07-16
AU2021328575A1 (en) 2023-03-16
KR20230053644A (ko) 2023-04-21
CN116096717A (zh) 2023-05-09

Similar Documents

Publication Publication Date Title
MX2023001929A (es) Derivados de 1h-pirrol[3,2-c]piridina y 1h-pirrol[2,3-c]piridina como inhibidores del receptor tipo troll 9 (tlr9) para el tratamiento de fibrosis.
MX2023001884A (es) Derivados de 1h-benzo[d]imidazol como inhibidores del receptor tipo toll 9 (tlr9) para el tratamiento de fibrosis.
BR112023002737A2 (pt) Derivados de imidazo[1,2-a]piridina e [1,2,4]triazolo[1,5-a]piridina como inibidores de tlr9 para o tratamento de fibrose
TN2022000039A1 (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors
NZ766835A (en) Pharmaceutical compounds
MX2024007058A (es) Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer.
PH12017501384A1 (en) Pharmaceutical compositions for combination therapy
MX379424B (es) Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis.
JP2016510769A5 (enExample)
IN2013MU01468A (enExample)
PH12012502528A1 (en) Pyrazolo [1, 5 -a] pyrimidines as antiviral agents
WO2005073224A3 (en) Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
PH12013501855A1 (en) Combination therapies for hematologic malignancies
MX2009004700A (es) Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
WO2008008539A3 (en) Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
JP2006507254A5 (enExample)
CA3073608C (en) [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
WO2010151488A1 (en) Combination of boceprevir with 5- ( { 6- [2, 4- bis (trifluoromethyl) phenyl] pyridazin-3 -yl } methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c] pyridine for the treatment of hcv
WO2003099223A3 (en) Copper lowering treatment of inflammatory and fibrotic diseases
WO2007014940A3 (en) Quinoline derivatives as antibacterical agents
MX2024006473A (es) Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y metodos para usar los mismos.
RU2019114228A (ru) ИНГИБИТОРЫ ДЕКАРБОКСИЛАЗЫ ПОЛУАЛЬДЕГИДА α-АМИНО-β-КАРБОКСИМУКОНОВОЙ КИСЛОТЫ
WO2025014877A3 (en) Triazolo wrn inhibitors
EP4578499A3 (en) Resmetirom for reducing liver volume